MEK inhibitors are a class of drugs that target the MEK protein, which plays a crucial role in the MAPK signaling pathway. This pathway is involved in cell division, growth, and survival, making MEK inhibitors particularly relevant in the treatment of certain types of cancer. By blocking MEK, these drugs can help slow down or stop the growth of cancer cells. These inhibitors are often used in combination with other therapies to enhance their effectiveness. They have shown promise in treating tumors with specific genetic mutations, such as those found in BRAF mutations. Ongoing research continues to explore their potential in various cancer types.